Abstract: A radiolabeled annexin comprising at least 2 up to 20 histidine residues at its N-terminus is disclosed. At least two of said histidine residues are adjacent or separated by no more than one other amino acid. The radiolabeled annexin is a stable complex with a radionuclide such as technetium 99m. The radiolabeled annexin can be used in a method of imaging cell death in a nucleated cell within a region of a mammalian subject in vivo.

Abstract: An Annexin A5 variant, comprising one or more RGD (Arg-Gly-Asp) sequences, is suitable for use in the treatment of a disease in mammals, including humans, wherein augmentation of phagocytosis is a desired effect of treatment. The Annexin A5 variant can e.g. be used in the treatment of chronic inflammatory diseases such as atherosclerotic plaque or in the treatment of COPD. At least one RGD sequence may substitute sequences of three amino acids within the range 1-19 or other regions of the amino acid sequences of Annexin A5; alternatively one or more RGD sequences may be part of an extension at the N-terminal side.

Abstract: The invention pertains to a method of reducing scar formation during wound healing by administering a phosphatidylserine-binding compound, in particular an annexin, to a subject in need thereof. The healing wound may be a skin damage, but it may also be a myocardium e.g. which is at risk of suffering or is recovering from a heart failure.

Abstract: The present invention provides methods and compositions for the treatment and diagnosis of diseases such as neoplastic diseases, neurodegenerative diseases, cardiovascular diseases, autoimmune diseases, and inflammatory diseases. The methods are based on the concept of pretargeting and include the administration of complexes comprising a recognizable compound A coupled to annexins, and the administration of complexes comprising of pharmaceutical or diagnostic compounds coupled to a compound B recognizing and binding to compound A to subjects. The compositions include annexins, annexin variants, that are not internalized by the target cells, derivatives thereof, and complexes thereof.

Abstract: The invention pertains to a method of reducing scar formation during wound healing by administering a phosphatidylserine-binding compound, in particular an annexin, to a subject in need thereof. The healing wound may be a skin damage, but it may also be a myocardium e.g. which is at risk of suffering or is recovering from a heart failure.

Abstract: The present invention provides methods and compositions for the treatment, diagnosis, and prevention of diseases, such as neoplastic diseases, neurodegenerative diseases, cardiovascular diseases, autoimmune diseases, and inflammatory diseases. The methods include the administration of pharmaceutical complexes comprising annexins coupled to pharmaceutical compounds or carriers to subjects. The present invention also provides methods and compositions for delivering therapeutic compounds into the diseased cells of a subject either to kill them, such as tumor cells, or to rescue them, such as cardiomyocytes and neurons. The compositions include annexins, annexin variants, derivatives thereof, and complexes thereof.